[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heart-transplant-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heart-transplant-infection":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,76,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100599072","phase-2-valganciclovir-vs-letermovir-for-cmv-prophylaxis-in-heart-transplant-100599072",false,"NCT07079735","Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant","VALganciclovir vs. LETermovir for Primary Prevention of CMV in Moderate to High-Risk Heart Transplant Recipients (The VALET-CMV Study)","VALET-CMV","Inclusion Criteria:\n\nPatients who are \\>18 years of age who have received a heart transplant and have not started their CMV prophylaxis regimen will be included.\n\nExclusion Criteria:\n\nHistory of or suspected CMV disease within 6 months prior is excluded.","ALL","18 Years","99 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE2","PHASE3","The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.",[29,30,31],"CMV Viremia","Heart Transplant Infection","Heart Transplant Failure and Rejection","RECRUITING","2025-09-22",{"date":35,"type":36},"2025-09-25","ACTUAL",{"date":38,"type":36},"2025-09-12",{"date":40,"type":22},"2029-01-17",{"name":42,"class":43},"Columbia University","OTHER",2,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100591942","intestinal-microsporidiosis-in-french-heart-transplant-recipients-carmic-100591942","NCT06986980","Intestinal Microsporidiosis in French Heart Transplant Recipients (CARMIC)","Intestinal Microsporidiosis in French Heart Transplant Recipients","CARMIC","Inclusion Criteria:\n\n* heart transplant patients diagnosed with intestinal microsporidiosis\n* diagnosis made before December 31, 2024 in France (metropolitan France and overseas territories)\n\nExclusion Criteria:\n\n-patient opposition",{"count":54,"type":22},39,"OBSERVATIONAL","The investigators propose to carry out a national retrospective study to collect epidemiological, biological, clinical and therapeutic data on microsporidiosis among heart transplant patients.",[58,30],"Microsporidiosis Intestinal",[60,61,62,63,64,65],"microsporidiosis","Enterocytozoon bieneusi","Encephalitozoon intestinalis","Encephalitozoon hellem","solid organ transplant","heart transplant","2025-06-27",{"date":68,"type":36},"2025-07-01",{"date":70,"type":36},"2025-05-05",{"date":72,"type":22},"2025-12",{"name":74,"class":43},"University Hospital, Clermont-Ferrand",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":75},"100548984","phase-1-levothyroxine-supplementation-for-heart-transplant-recipients-100548984","NCT06428097","Levothyroxine Supplementation for Heart Transplant Recipients","Levothyroxine Supplementation for Heart Transplant Recipients: A Randomized Control Trial","Levo","Inclusion Criteria:\n\n1. Participants must be listed for heart transplantation\n2. Age ≥18 years\n3. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Patients with pre-existing thyroid related condition including hypothyroidism, hyperthyroidism and malignancy\n2. Patients with a known allergy or intolerance to levothyroxine\n3. Patients participating in another study evaluating an investigational drug within the past 30 days.",{"count":85,"type":22},97,[87],"PHASE1","This will be a prospective, randomized study performed at a single tertiary referral academic medical center (University of California San Francisco, CA), evaluating the survival benefits of levothyroxine compared with no levothyroxine for patients who have undergone heart transplant. It will be double-blinded and placebo-control; participants will be randomized to receive levothyroxine or receive no levothyroxine.",[90,30],"Heart Transplant Failure","2025-04-28",{"date":93,"type":36},"2025-05-01",{"date":95,"type":36},"2024-03-29",{"date":97,"type":22},"2027-03-01",{"name":99,"class":43},"University of California, San Francisco",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":108,"maxAge":18,"enrollmentInfo":109,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":75},"100551740","complications-in-pediatric-mechanical-circulatory-assistance-evaluation-of-infection-management-100551740","NCT06464016","Complications in Pediatric Mechanical Circulatory Assistance: Evaluation of Infection Management.","Relapse of VAD Infections After Discontinuation of Anti-infective Therapies in Children.","VADINFECT","Inclusion Criteria:\n\n* patients under 18yo of age with Berlin Heart assisting device in Hospices Civils de Lyon, in France.\n\nExclusion Criteria:\n\n* patients over 18 yo at the time of BH assistance\n* unavailable documentation","1 Day",{"count":110,"type":22},47,"Heart failure is a major cause of mortality and morbidity in children. Heart transplantation can significantly improve the prognosis of patients with severe heart failure, but access is limited by a shortage of transplants.\n\nLong-term mechanical circulatory support is a major advance in the management of heart failure and can provide haemodynamic support while awaiting myocardial recovery or heart transplantation. The Berlin Heart (BH) EXCOR is the only long-term support system available for children.\n\nDespite technical and medical advances in circulatory support, infection is a common complication and a major cause of morbidity and mortality in patients on BH.\n\nThere are few studies on the management of infection with mechanical support. Current ISHLT (International Society for Heart and Lung Transplantation) recommendations are based on expert opinion and observational studies. Some experts recommend anti-infective therapy until transplantation for specific support infections or for support-associated infections with persistent bacteraemia.",[113,114,30],"Heart-Assist Devices","Infections","2025-01-27",{"date":117,"type":36},"2025-01-28",{"date":119,"type":36},"2023-07-04",{"date":121,"type":22},"2025-11-01",{"name":123,"class":43},"Claude Bernard University"]